A Phase 1/2 Multicentre Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability, pharmacokinetics,
immunogenicity, antitumour activity and pharmacodynamics of BMS-986012 alone and in
combination with nivolumab in patients with relapsed/refractory SCLC.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society